Balkan Journal of Medical Genetics

SARCOLEMMAL DEFICIENCY OF SARCOGLYCAN COMPLEX IN AN 18-MONTH-OLD TURKISH BOY WITH A LARGE DELETION IN THE BETA SARCOGLYCAN GENE
Diniz G1,*, Tekgul H2, Hazan F3, Yararbas K4, Tukun A5
*Corresponding Author: Associate Professor Gulden Diniz, Neuromuscular Disease Center, Tepecik Research Hospital, Kibris Sehitleri Cad. 51/11 Alsancak 35220, Izmir, Turkey. Tel: +90-232-362-5547. Fax: +90-232-362- 7144. E-mail: agdiniz@gmail.com
page: 71

DISCUSSION

By somatic cell hybridization and fluorescence in situ hybridization (FISH), it was proved that the SGCB gene contains six exons and is located on chromosome 4q12 [1-3]. The β-SGC, protein product of the SGCB gene, localizes at the sarcolemma and is expressed ubiquitously, although predominantly, in muscle. The SGCB gene defects cause LGMD-2E, which may also be a severe or mild clinical phenotype. Calf hypertrophy may be present. It was reported that there are Amish patients with β sarcoglycanopathy who are still ambulant in the fifth decade. In addition, LGMD-2E primarily affects skeletal muscles, while brain, peripheral nerve and cardiac function are largely preserved. The less severe cardiac dysfunction in patients with LGMD-2E was explained by the lesser expression of β-SGC in cardiac muscle [1,3,5-9]. Differing expression patterns of sarcoglycan components in heart and skeletal muscle could be the result of alternatively spliced transcripts in these tissues. Hitherto, only rare SGCB gene mutations causing cardiomyopathy have been reported [6,9]. We did not find any clinical evidence of cardiac involvement, decreased intellectual capacity or neuropathy demonstrated by electromyography in the patient described in this report. Immunohistochemical analysis of sarcolemmal proteins in muscle biopsy is an important part of the diagnostic evaluation of patients with MD. Reduced or absent sarcolemmal expression of one of the four SGCs can be found in patients with any type of LGMDs and also in patients with dystrophinopathies. It has previously been suggested that different patterns of SGC expression could predict the primary genetic defect, and that genetic analysis could be directed by these patterns [2,7-11]. However, Klinge et al. [12] reported that residual SGC expression could be highly variable and an accurate prediction of the genotype could not be achieved. Bonnemann et al. [4] also determined that the total loss of sarcolemmal SGCs was caused by defects in the SGCB gene. Therefore they recommended using antibodies against all four SGCs for immune analysis of skeletal muscle sections [1,4,7,8,12]. Similarly, a concomitant reduction in dystrophin and any of the SGCs may illustrate the importance of considering coexisting dystrophinopathies in patients with sarcoglycandeficient LGMD [1-3]. For this reason, it is not easy to decide whether the disease is a dystrophinopathy with defective expressions of SGCs or an LGMD with defective expression of dystrophin [1,7,8,10,12,13]. However, in the patient described in this report, expression of sarcolemmal dystrophin and molecular analysis of the dystrophin gene were diffusely normal and thus dystrophinopathies were ruled out. Araishi et al. [5] also reported that deficiency of β-SGC caused loss of all other sarcoglycans as well as loss of sarcospan in the sarcolemma. The authors concluded that β-SGC is an important protein for formation of the sarcoglycan complex and it may be to strengthen the dys-trophin axis connecting the basement membrane with the cytoskeleton. It is interesting to note that, despite total SGCs loss, patients could have mild to moderate clinical courses at least to their current ages [9]. In the reported case, we determined the expression defects of all four sar-colemmal proteins. Moreover, the expressions of other sarcolemmal proteins such as dystrophin, merosin, dystroglycans were normal. In addition, during 4 years of follow-up, there was no evidence to predict a severe clinical course except the muscle enzyme elevation and myopathic EMG finding. In summary, this report describes a large deletion of the SGCB gene, which causes the total loss of sarcolemmal SGC proteins and further emphasizes the importance of systematic analysis of all related genes, instead of limiting the analysis to the one SGC gene that is hypothesized to be the cause of the abnormalities. In this case report, we also highlight the complexity of staining patterns associated with sarcolemmal proteins and the importance of careful analysis of this staining pattern in order to narrow the differential diagnosis of muscular dystrophies. Declaration of Interest. The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Number 27 VOL. 27 (2), 2024	Number 27 VOL. 27 (1), 2024
Number 26 Number 26 VOL. 26(2), 2023 All in one	Number 26 VOL. 26(2), 2023
Number 26 VOL. 26, 2023 Supplement	Number 26 VOL. 26(1), 2023
Number 25 VOL. 25(2), 2022	Number 25 VOL. 25 (1), 2022
Number 24 VOL. 24(2), 2021	Number 24 VOL. 24(1), 2021
Number 23 VOL. 23(2), 2020	Number 22 VOL. 22(2), 2019
Number 22 VOL. 22(1), 2019	Number 22 VOL. 22, 2019 Supplement
Number 21 VOL. 21(2), 2018	Number 21 VOL. 21 (1), 2018
Number 21 VOL. 21, 2018 Supplement	Number 20 VOL. 20 (2), 2017
Number 20 VOL. 20 (1), 2017	Number 19 VOL. 19 (2), 2016
Number 19 VOL. 19 (1), 2016	Number 18 VOL. 18 (2), 2015
Number 18 VOL. 18 (1), 2015	Number 17 VOL. 17 (2), 2014
Number 17 VOL. 17 (1), 2014	Number 16 VOL. 16 (2), 2013
Number 16 VOL. 16 (1), 2013	Number 15 VOL. 15 (2), 2012
Number 15 VOL. 15, 2012 Supplement	Number 15 Vol. 15 (1), 2012
Number 14 14 - Vol. 14 (2), 2011	Number 14 The 9th Balkan Congress of Medical Genetics
Number 14 14 - Vol. 14 (1), 2011	Number 13 Vol. 13 (2), 2010
Number 13 Vol.13 (1), 2010	Number 12 Vol.12 (2), 2009
Number 12 Vol.12 (1), 2009	Number 11 Vol.11 (2),2008
Number 11 Vol.11 (1),2008	Number 10 Vol.10 (2), 2007
Number 10 10 (1),2007	Number 9 1&2, 2006
Number 9 3&4, 2006	Number 8 1&2, 2005
Number 8 3&4, 2004	Number 7 1&2, 2004
Number 6 3&4, 2003	Number 6 1&2, 2003
Number 5 3&4, 2002	Number 5 1&2, 2002
Number 4 Vol.3 (4), 2000	Number 4 Vol.2 (4), 1999
Number 4 Vol.1 (4), 1998	Number 4 3&4, 2001
Number 4 1&2, 2001	Number 3 Vol.3 (3), 2000
Number 3 Vol.2 (3), 1999	Number 3 Vol.1 (3), 1998
Number 2 Vol.3(2), 2000	Number 2 Vol.1 (2), 1998
Number 2 Vol.2 (2), 1999	Number 1 Vol.3 (1), 2000
Number 1 Vol.2 (1), 1999	Number 1 Vol.1 (1), 1998

About the journal ::: Editorial ::: Subscription ::: Information for authors ::: Contact